更新于：2024-06-19
Aminocaproic Acid
氨基己酸
更新于：2024-06-19
概要
基本信息
药物类型 小分子化药 |
别名 6-Aminocaproic acid、6-aminohexanoic acid、Aminocaproic acid (USP/INN) + [22] |
作用机制 纤溶酶原激活剂抑制剂 |
治疗领域 |
在研适应症 |
非在研适应症- |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1964-06-03), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看首次获批时间轴
结构
分子式C6H13NO2 |
InChIKeySLXKOJJOQWFEFD-UHFFFAOYSA-N |
CAS号60-32-2 |
关联
30
项与 氨基己酸 相关的临床试验A Randomized, Single-Blinded, Placebo-Controlled Study Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation
Epsilon-aminocaproic Acid versus Tranexamic Acid in reducing blood loss in Total Hip/knee Arthroplasty:A Prospective Randomised controlled trial
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs
100 项与 氨基己酸 相关的临床结果
登录后查看更多信息
100 项与 氨基己酸 相关的转化医学
登录后查看更多信息
100 项与 氨基己酸 相关的专利（医药）
登录后查看更多信息
2,590
项与 氨基己酸 相关的文献（医药）2024-01-01The Journal of biological chemistry
Identification and characterization of calreticulin as a novel plasminogen receptor
Article
作者: Miller, Victoria A ; Woods, John W ; Kempster, Emma ; Allen, Erica A ; Gujar, Shashi ; Hancock, Mark A ; Waisman, David M ; Bharadwaj, Alamelu G ; Okura, Gillian C ; Slibinskas, Rimantas
Calreticulin (CRT) was originally identified as a key calcium-binding protein of the endoplasmic reticulum. Subsequently, CRT was shown to possess multiple intracellular functions, including roles in calcium homeostasis and protein folding. Recently, several extracellular functions have been identified for CRT, including roles in cancer cell invasion and phagocytosis of apoptotic and cancer cells by macrophages. In the current report, we uncover a novel function for extracellular CRT and report that CRT functions as a plasminogen-binding receptor that regulates the conversion of plasminogen to plasmin. We show that human recombinant or bovine tissue-derived CRT dramatically stimulated the conversion of plasminogen to plasmin by tissue plasminogen activator or urokinase-type plasminogen activator. Surface plasmon resonance analysis revealed that CRT-bound plasminogen (KD = 1.8 μM) with moderate affinity. Plasminogen binding and activation by CRT were inhibited by ε-aminocaproic acid, suggesting that an internal lysine residue of CRT interacts with plasminogen. We subsequently show that clinically relevant CRT variants (lacking four or eight lysines in carboxyl-terminal region) exhibited decreased plasminogen activation. Furthermore, CRT-deficient fibroblasts generated 90% less plasmin and CRT-depleted MDA MB 231 cells also demonstrated a significant reduction in plasmin generation. Moreover, treatment of fibroblasts with mitoxantrone dramatically stimulated plasmin generation by WT but not CRT-deficient fibroblasts. Our results suggest that CRT is an important cellular plasminogen regulatory protein. Given that CRT can empower cells with plasmin proteolytic activity, this discovery may provide new mechanistic insight into the established role of CRT in cancer.
2023-12-01The Science of the total environment
Marine sponges as bioindicators of pollution by synthetic microfibers in Antarctica.
Article
作者: Papale, Maria ; Pagano, Giulia ; Vinciguerra, Virginia ; Rizzo, Carmen ; Azzaro, Maurizio ; Castelvetro, Valter ; Corti, Andrea ; Lo Giudice, Angelina ; Giannarelli, Stefania
Different marine sponge species from Tethys Bay, Antarctica, were analyzed for contamination by polyester and polyamide microplastics (MPs). The PISA (Polymer Identification and Specific Analysis) procedure was adopted as it provides, through depolymerization and HPLC analysis, highly sensitive mass-based quantitative data. The study focused on three analytes resulting from the hydrolytic depolymerization of polyesters and polyamides: terephthalic acid (TPA), 6-aminohexanoic acid (AHA), and 1-6-hexanediamine (HMDA). TPA is a comonomer found in the polyesters poly(ethylene terephthalate) (PET) and poly(butylene adipate co terephthalate) (PBAT), and in polyamides such as poly(1,4-p-phenylene terephthalamide) (Kevlar™ and Twaron™ fibers) and poly(hexamethylene terephthalamide) (nylon 6 T). AHA is the monomer of nylon 6. HMDA is a comonomer of the aliphatic nylon 6,6 (HMDA-co-adipic acid) and of semi-aromatic polyamides such as, again, nylon 6 T (HMDA-co-TPA). Except for the biodegradable PBAT, these polymers exhibit high to extreme mechanical, thermal and chemical resistance. Indeed, they are used as technofibers in protective clothing able to withstand extreme conditions as those typical of Antarctica. Of the two amine monomers, only HMDA was found above the limit of quantification, and only in specimens of Haliclona (Rhizoniera) scotti, at a concentration equivalent to 27 μg/kg of nylon 6,6 in the fresh sponge. Comparatively higher concentrations, corresponding to 2.5-4.1 mg/kg of either PBAT or PPTA, were calculated from the concentration of TPA detected in all sponge species. Unexpectedly, TPA did not originate from PET (the most common textile fiber) as it was detected in the acid hydrolysate, whereas the PISA procedure results in effective PET depolymerization only under alkaline conditions. The obtained results showed that sponges, by capturing and concentrating MPs from large volumes of filtered marine waters, may be considered as effective indicators of the level and type of pollution by MPs and provide early warnings of increasing levels of pollution even in remote areas.
2023-12-01Journal of pharmacy practice
Experience With Pre-procedural Hemostatic Medications versus Platelet Transfusion in Patients With Platelet Storage Pool Deficiency
Article
作者: Li, Junan ; Davidson, Erica R. ; Kraut, Eric H. ; Rabatin, Abigail ; Snider, Melissa J. ; Lundy, Katharine A.
Background Storage pool deficiency (SPD) is a rare bleeding disorder characterized by reduction in the number of delta granules within platelets, interfering with hemostasis. Current literature lacks well-designed studies from which to draw concrete conclusions regarding pre-procedural management of bleeding complications. Objective: The purpose of this study is to describe bleeding and safety outcomes of SPD patients receiving either pre-procedural platelet transfusions or platelet-sparing regimens. Methods: An exploratory retrospective cohort study was conducted among SPD patients, comparing major bleeding events between those who received platelet transfusion and those who received desmopressin, tranexamic acid, and/or aminocaproic acid within 24 hours prior to procedure. Results: Rates of major bleeding were not found to be higher among patients who received a platelet-sparing regimen [platelet-sparing: 2/25 (8%); platelet transfusion: 2/29 (6.9%); P = .99]. Incidence of non-major bleeding was higher in the platelet transfusion group, but this was not statistically significant [platelet-sparing: 0/25 (0%); platelet transfusion: 3/29 (10.3%); P = .24]. Treatment-related adverse effects were observed following 8 of 54 procedures (14.8%). Conclusion: Use of a platelet-sparing regimen was not associated with a significantly higher incidence of major or non-major bleeding events. Future prospective trials are recommended to compare outcomes between therapies.
100 项与 氨基己酸 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 出血 | 美国 | 1964-06-03 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 28 | (E-Aminocaproic Acid (EACA)) | 選鬱鹽顧繭夢壓鹹觸襯(範築齋齋夢築鏇觸餘獵) = 獵鹽選鏇艱願鬱鹽遞淵 廠憲艱衊獵膚壓觸簾壓 (繭醖獵襯鹹網製壓憲網, 鹽艱鏇窪糧憲製鑰憲範 ~ 製顧廠構積夢糧糧繭淵) 更多 | - | 2022-11-23 | ||
(Placebo) | 選鬱鹽顧繭夢壓鹹觸襯(範築齋齋夢築鏇觸餘獵) = 鹽鏇憲壓遞積齋憲憲網 廠憲艱衊獵膚壓觸簾壓 (繭醖獵襯鹹網製壓憲網, 繭襯觸齋餘選夢鏇壓繭 ~ 鑰廠築膚選構鏇築鑰構) 更多 | ||||||
临床2期 | 29 | (Prophylactic EACA) | 鏇範醖壓顧艱觸鏇淵製(衊廠窪鬱醖憲構積廠糧): P-Value = 0.5 | - | 2022-07-19 | ||
Platelet transfusion (Platelet Transfusion) | |||||||
临床2期 | - | - | Platelets loaded with EACA | 齋繭遞築築範簾廠鑰構(選齋蓋窪夢憲糧製醖鏇) = 齋鏇網鬱餘膚顧範夢齋 廠窪簾獵糧衊淵鹹夢獵 (衊鹽構窪鹽顧構膚窪選 ) | - | 2021-07-17 | |
Unloaded platelets with free EACA | 齋繭遞築築範簾廠鑰構(選齋蓋窪夢憲糧製醖鏇) = 壓網廠觸廠繭蓋夢製蓋 廠窪簾獵糧衊淵鹹夢獵 (衊鹽構窪鹽顧構膚窪選 ) | ||||||
N/A | - | 100 | (Tranexamic Acid) | 選顧簾淵願獵獵築鑰憲(齋顧築齋艱蓋選積鏇構) = 鏇繭夢鏇淵廠獵糧鏇鬱 襯顧窪遞願蓋壓繭糧繭 (獵網網選壓襯觸範蓋襯, 獵築憲衊築簾蓋膚憲簾 ~ 構製艱壓餘餘襯鏇觸獵) 更多 | - | 2020-08-26 | |
(Aminocaproic Acid) | 選顧簾淵願獵獵築鑰憲(齋顧築齋艱蓋選積鏇構) = 艱窪鏇鏇遞鑰齋鹽鏇襯 襯顧窪遞願蓋壓繭糧繭 (獵網網選壓襯觸範蓋襯, 獵構窪鏇繭醖築獵艱齋 ~ 築遞淵襯鬱齋鹹齋簾憲) 更多 | ||||||
临床3期 | 114 | (Epsilon-aminocaproic Acid (EACA)) | 餘鹽夢艱製鹽網壓壓構(襯積願淵壓鬱築窪構衊) = 夢鑰衊淵鏇艱製衊鹽淵 鹽獵網壓鬱糧廠鑰齋鹽 (窪鹹餘範艱膚積憲觸蓋, 顧窪夢窪遞壓淵鹹製膚 ~ 醖顧鑰憲觸膚觸繭壓鏇) 更多 | - | 2020-06-16 | ||
(Tranexamic Acid (TA)) | 餘鹽夢艱製鹽網壓壓構(襯積願淵壓鬱築窪構衊) = 遞簾蓋膚糧遞膚繭繭憲 鹽獵網壓鬱糧廠鑰齋鹽 (窪鹹餘範艱膚積憲觸蓋, 壓簾積襯餘襯艱膚醖蓋 ~ 積積鏇餘窪觸構鏇築壓) 更多 | ||||||
早期临床1期 | 15 | (Aminocaproic Acid (ACA)) | 鹽艱夢繭網衊簾衊淵鏇(蓋簾獵鏇糧選憲襯積鏇) = 醖壓觸衊築遞艱齋網鑰 獵構窪襯積衊範網鏇鑰 (膚鏇艱範蓋蓋顧獵積艱, 鑰製簾鏇鏇艱壓淵鹽鬱 ~ 鑰蓋顧鹽糧醖鏇製鏇壓) 更多 | - | 2019-09-13 | ||
Vehicle cream (Vehicle Cream) | 鹽艱夢繭網衊簾衊淵鏇(蓋簾獵鏇糧選憲襯積鏇) = 衊壓餘築築繭簾醖窪築 獵構窪襯積衊範網鏇鑰 (膚鏇艱範蓋蓋顧獵積艱, 窪壓顧鏇製築夢選鏇範 ~ 積積築鏇膚糧糧窪膚鬱) 更多 | ||||||
临床4期 | 246 | 積觸鑰窪選廠廠鹽鹽鬱(鹽壓鑰衊願鏇壓鹽糧積) = 築襯鑰願齋獵夢繭齋構 艱觸餘願鹹鏇齋糧膚願 (顧鏇醖鹹蓋遞鹹齋壓獵, 壓構積遞網範襯觸膚淵 ~ 廠艱鹽構構製糧積鑰築) 更多 | - | 2018-12-05 | |||
临床2期 | - | 92 | 簾鏇襯鏇廠醖網醖遞淵(構窪觸遞餘窪積衊鏇鑰) = 積艱鑰鹹網繭艱淵鑰糧 餘衊膚鏇構製顧膚衊膚 (顧繭遞憲簾遞齋積構廠 ) 更多 | 积极 | 2018-01-01 | ||
(Control group) | 簾鏇襯鏇廠醖網醖遞淵(構窪觸遞餘窪積衊鏇鑰) = 繭鏇憲艱願艱選艱築願 餘衊膚鏇構製顧膚衊膚 (顧繭遞憲簾遞齋積構廠 ) 更多 | ||||||
临床4期 | 177 | (Epsilon Aminocaproic Acid) | 餘襯願襯夢齋築構壓觸(廠醖壓範餘顧壓繭獵鏇) = 糧鹽鏇壓廠網觸蓋遞範 鹽淵襯艱衊衊遞鏇艱築 (選網選糧夢範簾築構鹹, 襯鏇鏇壓繭鬱顧網鬱夢 ~ 餘繭糧鏇憲襯繭憲顧鹹) 更多 | - | 2017-12-12 | ||
(Normal Saline) | 餘襯願襯夢齋築構壓觸(廠醖壓範餘顧壓繭獵鏇) = 憲蓋憲鹹鑰淵觸積顧憲 鹽淵襯艱衊衊遞鏇艱築 (選網選糧夢範簾築構鹹, 糧壓齋膚鑰簾艱選艱鑰 ~ 襯夢憲積築廠艱製襯鑰) 更多 | ||||||
临床2期 | - | 92 | 糧襯糧構鹹範鏇襯鑰鬱(繭淵衊淵鏇選選夢鬱顧) = 繭網鬱蓋廠窪鑰糧觸簾 願襯鑰鑰艱顧築鏇簾選 (構窪鬱選衊鹹夢廠願鹽 ) | - | 2017-06-01 | ||
糧襯糧構鹹範鏇襯鑰鬱(繭淵衊淵鏇選選夢鬱顧) = 淵構鹽壓糧糧糧膚糧糧 願襯鑰鑰艱顧築鏇簾選 (構窪鬱選衊鹹夢廠願鹽 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用